Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CAR-T Cell Therapy Shows Lasting Results in Two Pediatric Patients



While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

Share this!

January 27, 2017 | by Sarah Hand, M.Sc.

Two pediatric patients with leukemia have been in remission for over a year after receiving experimental CAR-T cell therapy. While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

The two girls – 11-months-old and 16-months-old at the time of treatment – are both doing well over a year after receiving the modified CAR-T cells. The doctors at Great Ormond Street Institute of Child Health, University College London, who administered the experimental treatment have now presented the case studies in an article published in the journal, Science Translational Medicine.

The cases involved the use of so-called “off-the-shelf” CAR-T cells to target cancer cells. CAR-T cell therapy normally involves gene editing a patient’s own immune cells to allow them to destroy tumor tissue.

While this approach has been shown to be relatively safe and effective, it requires an expensive and laborious procedure of collecting enough immune cells from the patient to be edited. If a patient is very young or very sick, the number of viable immune cells may be limited.

If a patient were to be infused with off-the-shelf cells which are not their own, it’s likely that the foreign cells would attack their body in a phenomenon known as graft-versus-host disease. To combat this response, pharmaceutical company Cellectis developed a gene editing tool to turn off the gene, called TCRαβ, responsible for allowing the donor cells to attack the host.

Cellectis’ gene editing tool allowed for the creation of UCART19 cells which could be universally accepted by patients with B-cell acute lymphoblastic leukemia. However, because the gene editing tool is not 100 percent accurate, both pediatric patients treated with the UCART19 cells developed some signs of graft-versus-host disease.

A gene editing technique known as TALEN was used by Cellectis to silence TCRαβ, however researchers are now looking to CRISPR for an easier and less-expensive gene editing tool. CRISPR-edited cells are now being assessed in two cancer clinical trials taking place in the US and China.

Keywords: CAR-T, Gene Editing, Leukemia


Share this with your colleagues!

Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News

Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News

Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


Electronic Informed Consent: 2017 Industry Survey Results

Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time

The Modernization of eCOA Technology for Clinical Trials

Developing a Biological Safety Evaluation

Copyright © 2016-2017 Honeycomb Worldwide Inc.